June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Preclinical evaluation of rAAV8.PDE6A in the Pde6aD670G mutant mouse model of RP43
Author Affiliations & Notes
  • Christian Schön
    Center for Integrated Protein Science Munich CiPSM at the Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany
  • Regine Mühlfriedel
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
  • Vithiyanjali Sothilingam
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
  • Francois Paquet-Durand
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
  • Bernd Wissinger
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
  • Mathias W Seeliger
    Institute for Ophthalmic Research, Centre for Ophthalmology, University of Tübingen, Tübingen, Germany
  • Martin Biel
    Center for Integrated Protein Science Munich CiPSM at the Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany
  • Stylianos Michalakis
    Center for Integrated Protein Science Munich CiPSM at the Department of Pharmacy – Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Germany
  • Footnotes
    Commercial Relationships   Christian Schön, EyeServ (P); Regine Mühlfriedel, None; Vithiyanjali Sothilingam, None; Francois Paquet-Durand, None; Bernd Wissinger, None; Mathias Seeliger, EyeServ (P); Martin Biel, EyeServ (P); Stylianos Michalakis, EyeServ (P)
  • Footnotes
    Support  Tistou and Charlotte Kerstan Foundation
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4500. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Christian Schön, Regine Mühlfriedel, Vithiyanjali Sothilingam, Francois Paquet-Durand, Bernd Wissinger, Mathias W Seeliger, Martin Biel, Stylianos Michalakis; Preclinical evaluation of rAAV8.PDE6A in the Pde6aD670G mutant mouse model of RP43. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4500.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Mutations in the phosphodiesterase 6 alpha (PDE6A) gene are known to cause retinitis pigmentosa type 43 (RP43) – A currently cureless blinding disease. Here, a novel recombinant adeno-associated virus (AAV) vector for gene supplementation therapy of PDE6A-linked RP was developed and tested for efficacy in the preclinical Pde6aD670G mouse model of RP43.

Methods : An AAV-based gene supplementation vector coding for full length human PDE6A under control of the human, rod-specific rhodopsin promoter was generated and used for packaging of AAV8-pseudotyped vectors. The resulting vector (rAAV8.PDE6A) was tested for efficacy by subretinal injections in two-week old Pde6aD670G mutant mice with short-term and long-term analysis at 4 weeks and 6 months post-injection, respectively. AAV vector-mediated expression of human PDE6A protein was assessed by immunohistochemistry using a PDE6A-specific antibody combined with confocal microscopy. Efficacy was assessed by measuring morphological preservation in vivo using optical coherence tomography (OCT) and ex vivo by analyzing histological cross-section of treated and untreated retinas.

Results : We designed and generated rAAV8.PDE6A, a novel AAV vector optimized for efficient PDE6A gene expression in human rod photoreceptors. Transgene expression assay of rAAV8.PDE6A confirmed efficient and specific human PDE6A protein expression that localized to rod photoreceptor outer segments. A biological activity assay for rAAV8.PDE6A based on analysis of morphological preservation confirmed a beneficial effect of the treatment at both observation time points. Additionally, we found a preservation of rod outer segment structure and prolonged survival of cone photoreceptors up to 6 months after treatment.

Conclusions : The novel rAAV8.PDE6A vector supports efficient and specific transgene expression and biological activity in the preclinical Pde6aD670G mouse model of RP43.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×